Attention deficit hyperactivity disorder medications in children with heart disease
1University of California - Davis, Sacramento, California, USA.
Insights
Stimulant medications for attention deficit hyperactivity disorder (ADHD) appear safe for children with congenital heart disease. Consultation with a pediatric cardiologist is recommended for those with known or suspected cardiac conditions.
Area of Science:
- Pediatric Cardiology
- Neurodevelopmental Disorders
- Pharmacology
Background:
- Attention deficit hyperactivity disorder (ADHD) is prevalent in children, with higher incidence in those with congenital heart disease (CHD).
- Concerns exist regarding the cardiovascular safety of ADHD medications, particularly stimulant drugs, due to reported adverse events.
Purpose of the Study:
- To review the effects and safety of ADHD medications in pediatric patients with known or undiagnosed CHD.
- To address the controversy surrounding ADHD medication use in this vulnerable population.
Main Methods:
- Review of current data and existing literature on ADHD medication safety in pediatric patients with cardiovascular conditions.
- Analysis of concerns regarding cardiovascular risks associated with stimulant medications.
Main Results:
- Available data indicate no evidence of serious adverse cardiovascular events in children with CHD treated with stimulant ADHD medications.
- Cardiovascular evaluation is advised for patients with known or suspected cardiac disease before initiating ADHD medication.
Conclusions:
- Stimulant ADHD medications are generally considered safe for children with CHD.
- Coordination between primary care physicians, ADHD prescribers, and pediatric cardiologists is crucial for optimal patient care and medication selection.
Purpose Of Review:
Attention deficit hyperactivity disorder (ADHD) is quite common in the general pediatric population, Its incidence is thought to be even higher in the population of patients with congenital heart disease, especially in those patients with complex disease and who have had cardiac surgical interventions early in life. There has been controversy as to the safety of ADHD medications, especially in the latter population of patients. This compendium is meant to review the effects of the ADHD medications and the safety of these medications in patients with either known or undiagnosed congenital heart disease.
Recent Findings:
The concern with regard to the use of ADHD medications has been as a result of the reports of sudden unexpected deaths among patients taking stimulant drugs for ADHD. Therefore, the question of whether or not stimulant drugs increase the risk of adverse cardiovascular events has led to a discussion of the appropriate use of these drugs in patients with known cardiovascular disease, as well as a discussion as to the appropriate evaluation in order to identify undiagnosed 'at-risk' patients with congenital heart disease or arrhythmias. This article will review and amplify these discussions, as well as the conclusions that have come forth as a result of these discussions.
Summary:
Currently available data suggest that there is no evidence for serious adverse cardiovascular complications in children with known cardiovascular diseases including patients of congenital heart disease who are treated with stimulant medications. Despite this, if the patient does have known cardiac disease, or if the history and physical examination is suggestive of cardiac disease, it is suggested that consultation/evaluation with a pediatric cardiologist occur. It is extremely unlikely that stimulant medications would be contraindicated in almost any condition that falls under this category. However, a few specific cardiac conditions might tailor the choice of the specific ADHD medication. Therefore the coordination of care between the primary care physician, the ADHD medication-prescribing physician, and the pediatric cardiologist may be very important in this circumstance.
More Related Videos
05:48The Adventures of Fundi Intervention Based on the Cognitive and Emotional Processing in Attention Deficit Hyperactive Disorder Patients
Published on: June 12, 2020
13:09Using Brain Activation nir-HEG/Q-EEG and Execution Measures CPTs in a ADHD Assessment Protocol
Published on: April 1, 2018
Related Concept Videos
Attention-Deficit/Hyperactivity Disorder
Diagnostic Criteria and Symptoms
To diagnose ADHD, symptoms must manifest before age 12 and be evident across multiple settings....
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers
Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic Agonists: Therapeutic Uses
Emergency and Intensive Care Unit (ICU) applications: Pressor agents increase blood pressure, heart rate, and contractility in shock and organ failure situations. Dopamine can induce vasodilation and stimulate adrenoceptors. Endogenous catecholamines are effective in treating cardiogenic shock. α2-agonists like clonidine can reverse anesthesia-induced hypertension.
Allergies and...
Cardiovascular Drugs: Classification based on Therapeutic Indications
Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
